How do you manage venous thromboembolic events or bleeding events in RCC or HCC patients on anti-angiogenic TKIs?

I generally would not discontinue for a bleeding event for an RCC pts on anti-VEGF therapy. I may hold drug while managing the event if I can control the source of bleeding, but given most options include such an approach would restart cautiously. Similarly for venous thrombotic events I would manag...